If enacted, the legislation would update the CLIA framework for laboratory-developed tests while reaffirming CMS oversight of LDTs.
By Clarisa Blattner, CCS, CPC
For years, the debate surrounding laboratory developed test (LDT) oversight has centered on a fundamental question: Should modern diagnostic testing be regulated primarily as a medical device or as a professional laboratory service?
With the introduction of H.R. 8890, the “Enhancing Clinical Laboratory Innovation and Access Act” (Enhancing CLIA Act), Congress may be signaling a meaningful shift in that conversation.
Introduced in May by Representative Neal Dunn, the bill proposes modernization of the CLIA framework while reaffirming that LDTs fall under the oversight of the Centers for Medicare & Medicaid Services (CMS) through CLIA rather than through the Food and Drug Administration’s (FDA) traditional medical device framework.
As molecular diagnostics and genomic medicine continue to evolve, the bill seeks to update the CLIA framework to reflect advances in laboratory science while clarifying CMS’ oversight of LDTs.
The Regulatory Context Behind the Legislation
The laboratory industry has spent much of the past several years responding to the FDA’s efforts to expand oversight of LDTs through medical device authorities. Many laboratories, professional organizations, and industry stakeholders argued that while modernization of oversight was appropriate, applying a traditional FDA device model to laboratory testing could introduce duplicative regulation, increase operational burdens, slow innovation, and potentially reduce patient access to advanced diagnostics.
These concerns became particularly pronounced as precision medicine evolved beyond traditional laboratory workflows. Today’s diagnostics increasingly involve:
- next-generation sequencing (NGS),
- molecular residual disease (MRD) testing,
- AI-assisted interpretation,
- longitudinal genomic analysis,
- and software-driven clinical insights.
Many stakeholders argued that these technologies do not fit neatly within conventional device regulatory paradigms developed decades earlier.
The Enhancing CLIA Act appears to reflect a policy effort to modernize oversight without fundamentally restructuring the laboratory industry around a device-centric framework.
What the Enhancing CLIA Act Proposes
The legislation outlines several significant provisions intended to update CLIA for modern diagnostic environments.
Among its key components, the bill would:
- reaffirm that LDTs are professional laboratory services regulated under CLIA,
- direct CMS to establish a public database containing validation and performance information for LDTs,
- clarify that LDTs include advanced analyses of digital laboratory information, including genomic data derived from previously sequenced patient samples,
- create pathways for voluntary third-party confirmation of analytical and clinical validity,
- and strengthen centralized error reporting and CMS oversight authorities when concerns regarding test validity arise.
Rather than eliminating oversight, the bill proposes updating how LDTs are regulated while adding new transparency and reporting requirements.
A Shift Toward Laboratory-Centered Oversight
One of the most notable aspects of the bill is its apparent recognition that modern diagnostics operate differently from traditional manufactured medical devices.
Unlike mass-produced devices, many LDTs are developed, validated, and continuously refined within CLIA-certified laboratories by multidisciplinary teams of pathologists, laboratory directors, geneticists, bioinformaticians, and clinical scientists. In many cases, laboratories rapidly adapt assays based on emerging scientific evidence, evolving biomarkers, new therapeutic targets, and updated clinical guidelines.
This flexibility became especially visible during the COVID-19 pandemic, when laboratories rapidly developed and deployed testing capabilities in response to urgent public health needs.
The Enhancing CLIA Act appears to acknowledge these operational realities while still supporting enhanced transparency and accountability measures.
The bill’s inclusion of digital laboratory analyses and genomic reinterpretation is particularly noteworthy because it recognizes the growing role of computational medicine and longitudinal data interpretation in modern diagnostics. These capabilities are becoming increasingly important in oncology, rare disease testing, pharmacogenomics, and precision medicine initiatives.
Potential Industry Implications
While many laboratories may view the legislation positively, the bill could also introduce new operational considerations.
The proposed public database may increase transparency for providers, patients, and payors, potentially improving confidence in laboratory testing and facilitating greater visibility into test performance characteristics. However, questions remain regarding:
- reporting requirements,
- administrative burden,
- proprietary information protections,
- and the standardization of validation expectations.
Similarly, while the bill describes third-party validity confirmation as voluntary, market dynamics may ultimately influence adoption. Commercial payors, health systems, and employers could begin viewing independent validation as a differentiator when evaluating diagnostic offerings or coverage policies.
The legislation may also influence future reimbursement and market access discussions, particularly as stakeholders continue seeking stronger evidence frameworks for advanced diagnostics and precision medicine applications.
Implementation details will therefore matter significantly if the legislation advances.
What Comes Next
The Enhancing CLIA Act remains early in the legislative process, and substantial policy discussions are likely ahead. Questions surrounding transparency standards, clinical validity expectations, CMS oversight authority, and operational implementation will likely generate extensive industry dialogue.
Nevertheless, the bill represents an important development in the broader evolution of LDT oversight policy.
For years, much of the laboratory industry argued that modernization was necessary, but that modernization should occur through an updated CLIA framework rather than through expansion of FDA device regulation. The Enhancing CLIA Act suggests that lawmakers may increasingly be considering that approach.
As diagnostics continue advancing beyond traditional testing models into AI-enabled interpretation, genomic analytics, and data-driven precision medicine, the need for a modernized regulatory framework will only continue to grow.
The central policy question may no longer be whether oversight should evolve, but rather how to modernize oversight in a way that preserves innovation, operational agility, and patient access while ensuring transparency, quality, and clinical confidence.
The Enhancing CLIA Act may represent one of the clearest signals yet that Congress is beginning to define what that future could look like.
About the author: Clarisa Blattner, CCS, CPC, is senior director of revenue and payor optimization at XiFin.
